Author:
Munde Manojkumar K., ,Kulkarni Nilesh S.,Rukhe Nikita B.,Sen Ashim K.,Sen Dhanya B.
Abstract
A stability indicating reversed-phase high-performance liquid-chromatographic method for analysis of empagliflozin was developed and validated as per the ICH guidelines. Statistical design of experiment was applied for optimization, where independent variables used were methanol proportions in mobile phase and flow rate. Experiment was carried out on an analytical reversed phase column Cosmosil C18 (250 × 4.6 mm, 5 µm). Based on the results obtained from these studies, suitable mobile phase with appropriate composition was selected and utilized for method development applying DoE approach. The mobile phase used was methanol: water (85:15 V/V). The flow rate was set at 0.8 mL min-1 and UV detection was carried out at 225 nm. The retention time of empagliflozin was found to be 4.259 min. The lower solvent consumption along with the short analytical run time (≤05 minute) provides a cost effective and environment friendly chromatographic procedure. The measured signal was shown to be precise, accurate and linear over the concentration range tested (10-50 µg mL-1) with a correlation coefficient of 0.9999. Thus, the proposed methodology is rapid, selective and requires simple sample preparation steps and represents a good procedure for analysis of empagliflozin. Central Composite Design (CCD) was used for method development of empagliflozin. Two factors were selected with eight center points and response of empagliflozin was measured in terms of retention time which dependent on two factors namely, methanol content in mobile phase and flow rate. CCD was effective means in optimization of HPLC for analysis of empagliflozin in pharmaceutical formulation. The stability of the drug was examined over different stress conditions as per International Conference on Harmonization (ICH) guidelines. Results obtained from the force degradation studies indicated that the developed method is appropriate for stability studies.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference14 articles.
1. 1. Inzucchi S. E., Zinman B., Fitchett D., Wanner C. and Schumacher M.: How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, 2018, 41(2) 356-363.
2. 2. Hinnen D.: Short commentary on empagliflozin and its potential clinical impact, Ther. Adv. Endocrinol. Metab., 2015, 6(2) 68-81.
3. 3. Padmaja N. and Veerabhadram G.: Method development and validation of RP-HPLC method for the estimation of empagliflozin in API, Int. J. Pharm. Sci. Res., 2016, 7(2) 724-727.
4. 4. Siridevi M. P., Kumar H. T., Rao S. Y. and Rao V. P. K.: RP-HPLC Method for Quantification of Empagliflozin in Pharmaceutical Formulation, Asian J. Pharm. Technol., 2019, 9(3) 208-211.
5. 5. Shirisha V., Krishnaveni B., Illendula S., Rao K. N. V. and Dutt H. R.: A new simple method development, validation and forced degradation studies of empagliflozin by using RP-HPLC, Int. J. Pharm. Biol. Sci., 2019, 9(1) 25-35.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献